Research finds positive benefits for cannabis for postmenopausal symptoms

49 0

Women can find relief in cannabis after going through menopause

Cannabidiol (CBD) is a compound derived from cannabis that has been gaining popularity in recent years, mainly thanks to numerous studies. It may be a potential solution for several conditions, including the menopausal phases. One study has found that this famous compound has sufficient benefits to improve the quality of life of women facing post-menopausal disorders.

Thanks to the increased access to medical cannabis, the premise of the study was to take a closer look at the effects that CBB may have to be considered as a possible treatment for postmenopausal women, whose ovaries no longer produce estrogen. The results were obtained after studying the behavior of animals.

The postmenopausal phase comprises several years after menopause, meaning, the cessation of menstruation. This stage begins at different times depending on each woman and lasts until approximately 65 years of age. CBD, being used mainly to treat pain and inflammation, seems to be an ally for all women going through this cycle.

According to the study, conducted by researchers at Rutgers University, cannabis has become increasingly popular among women to treat menopause-related symptoms. They reported that when estrogen-deficient mice were fed CBD, they showed remarkable improvement in several areas.

Apparently, the animals’ bloodstreams were able to easily clear glucose and they burned more energy. In addition, bone density was greatly improved, they had higher levels of beneficial gut bacteria, and they had less inflammation in their intestinal and bone tissues.

“This preclinical study is the first to suggest the therapeutic potential of CBD for alleviating symptoms of estrogen deficiency,” assures Diana Roopchand, an assistant professor and senior author of the study. “There is much anecdotal evidence of CBD’s health benefits for menopausal and postmenopausal women, but our study is the first to investigate some of the claims in an established preclinical model of postmenopause.”